Latest News about TAK
Recent news which mentions TAK
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
December 18, 2024
From Benzinga
Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst
December 03, 2024
From Benzinga
AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients
November 14, 2024
From Benzinga
Urgency, Debate Mark COP29 As Leaders Push For Carbon Market Rules, Worry About Trump
November 12, 2024
From Benzinga
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside
October 17, 2024
From Benzinga
Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization
October 04, 2024
From Benzinga
Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines
September 10, 2024
From Benzinga
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
September 09, 2024
From Benzinga
Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production
September 06, 2024
From Benzinga
Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues
August 12, 2024
From Benzinga
From Benzinga
Tickers
TAK
From InvestorPlace
3 Biotech Stocks to Buy on the Dip: July 2024
July 29, 2024
From InvestorPlace
Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation
July 24, 2024
From Benzinga
Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst
July 09, 2024
From Benzinga
From Benzinga
NextEra Energy, Lennar And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
June 18, 2024
From Benzinga
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
June 17, 2024
From Benzinga
What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?
June 17, 2024
From Benzinga
From Benzinga
7 F-Rated Stocks to Avoid at All Costs in June
June 06, 2024
From InvestorPlace
From Benzinga
From InvestorPlace
From Benzinga
From Benzinga
Why Is AC Immune (ACIU) Stock Up 45% Today?
May 13, 2024
From InvestorPlace
Japan's Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50%
May 09, 2024
From Benzinga
Tickers
TAK
From InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
|
|
|